Author: Sadık Etka Bayramoğlu (Turkey)
Co-authors: Nihat Sayin
Purpose
A randomized prospective study showed that intravitreal bevacizumab (IVB) is superior to laser therapy in refractive results in infants with zone Ⅰ and posterior zone Ⅱ retinopathy of prematurity (ROP). Although pre-treatment retinal vascularization is roughly divided into two zones according to The International Classification of Retinopathy of Prematurity revisited, the amount of retinal vascularization is in a wide spectrum. While retinal vascularization is classified as zone Ⅰ and zone Ⅱ, retinal vascularization may be at different stages within both zones. Even in eyes diagnosed with the plus disease by the same expert, the severity of the plus disease may vary between the eyes. The aim of the study is to investigate the relationship between refractive outcomes and retinal vascularization and plus disease by quantitatively measuring retinal vascularization and subjectively classifying plus disease in infants treated with IVB.
Setting/Venue
Health Sciences University, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Tertiary ROP Center
Methods
Retrospective, case series. Between May 2018 and December 2019, the patient charts of 142 babies who were treated with IVB with the diagnosis of Type 1 ROP or APROP and whose pre-treatment fundus photos were taken were retrospectively analyzed. 171 eyes of 93 infants whose at least one refraction measurement was recorded in the patient chart were included in the study. Pre-treatment and final images were taken with the Panocam Pro with a 130-degree viewing angle. Quantitative measurements were performed on the recorded images with the Image J program. Optic disc fovea distance (ODF), temporal retinal vascularization distance (TRVD), pre-treatment shortest retinal vascularization distance (SRVD), and final TRVD distance were measured. TRVD is the measurement of the length starting from the center of the optic disc, passing through the fovea, and extending to the avascular border. SRVD is the measurement of the shortest length to the avascular border in any quadrant. The pre-treatment severity of plus was scored subjectively between 1 and 3. The spherical equivalent (SE) was measured with the Plusoptix A09 instrument after cycloplegia.
Results
The mean gestational age (GA) and treatment week were 28.9 ± 2.5 and 36.6 ± 2.5 postmenstrual weeks (PMW), respectively. Additional IVB therapy was performed to 10 eyes, and laser photocoagulation was performed to 40 eyes during follow-up. The mean age of laser application was 53.1 ± 14.0 PMW. The mean age for final photography and refraction examination were 9.0 ± 3.5 and 18.1 ± 5.7 months, respectively. The final SE was 0.50 ± 2.56 diopters. The pre-treatment SRVD / ODF ratio was 2.2 ± 0.7, and the TRVD / ODF ratio was 2.5 ± 0.6. The final TRVD / ODF ratio was 4.0 ± 0.7. There was no significant correlation between final SE and GA, birth weight (BW), presence of type 1 ROP or ARPOP, IVB dose, and presence of additional IVB or laser treatments. There was a positive correlation between final SE and SRVD / ODF, TRVD / ODF, and final TRVD / ODF (p = 0.000, r = 0.281; p = 0.000, r = 0.267; p = 0.11, r = 0.234). There was a negative correlation between final SE and severity of plus before treatment (p = 0.009, r = -0.199).
Conlusions
Gestational age, BW, IVB dose, presence of additional IVB or laser treatments were not associated with refractive outcome. As retinal vascularization increases in pre-treatment and final images, refractive outcomes have become more hyperopic. As the severity of plus disease increases, refractive outcomes have become more myopic. Our study indicates that the main factors determining refractive outcome in infants treated with IVB are pre-treatment retinal vascularization and the severity of plus, which are the main factors that show the severity of the disease during the first treatment.
Financial Disclosure
We declare that we have no financial relationship with companies.
Comments
-